Nuwellis to Present at the Oppenheimer 33rd Annual Healthcare Conference
Nuwellis, Inc. (Nasdaq: NUWE), a medical technology firm, announced its participation in the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023. Nestor Jaramillo, President and CEO, and Lynn Blake, CFO, will present at 9:20 AM ET and hold investor 1x1 meetings. The presentation will be available via a webcast on the company's website, where it will also be archived for later access. Nuwellis focuses on transforming patient care for those with fluid overload through its Aquadex SmartFlow® system, aimed at providing effective ultrafiltration therapy.
- None.
- None.
MINNEAPOLIS, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that Nestor Jaramillo, President and Chief Executive Officer, and Lynn Blake, Chief Financial Officer, will participate in the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023.
Nuwellis will give a corporate presentation on Tuesday, March 14, 2023, at 9:20 AM ET and host investor 1x1 meetings, which can be requested through Oppenheimer. The webcast presentation will be available for viewing on the Company's website at ir.nuwellis.com and will be archived and available for replay.
About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The Company is focused on commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland. For more information visit www.nuwellis.com or visit us on LinkedIn and Twitter.
About the Aquadex SmartFlow® System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
CONTACTS
INVESTORS:
Vivian Cervantes
Gilmartin Group
ir@nuwellis.com
MEDIA:
Annika Parish
Health+Commerce
annika@healthandcommerce.com
FAQ
When is Nuwellis participating in the Oppenheimer Healthcare Conference?
What time will Nuwellis present at the Oppenheimer Conference?
Where can I watch the Nuwellis conference presentation?
What is the focus of Nuwellis as a medical technology company?
What is the Aquadex SmartFlow® system?
